Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 587-593

  Yoneda, Suguru ^a   Umemura, Takeji ^a   Joshita, Satoru ^a   Ichijo, Tetsuya ^a   Matsumoto, Akihiro ^a   Yoshizawa, Kaname ^a   Katsuyama, Yoshihiko ^b   Ota, Masao ^a   Tanaka, Eiji ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemokines; Core; Interferon sensitivity determining region; MIP 1 ; Pegylated interferon; Ribavirin

Indexed keywords

CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PEGINTERFERON ALPHA2B; RANTES; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; CYTOKINE PRODUCTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 79957557703     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00802.x     Document Type: Article

References (30)

1. Kiyosawa K, Sodeyama T, Tanaka E etal. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
2. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37 (Suppl 2): S95-S100.
3. Umemura T, Ichijo T, Yoshizawa K etal. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 (Suppl 19): 102-7.
4. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
5. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14: 675-87.
7. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009; 49: 676-88.
8. Umemura T, Zen Y, Hamano H etal. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46: 463-71.
9. Shirakawa H, Matsumoto A, Joshita S etal. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60.
10. Kato N, Hijikata M, Ootsuyama Y etal. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-8.
11. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
12. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
13. Yoneda S, Umemura T, Katsuyama Y etal. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011; 203: 1087-95.
14. Shields PL, Morland CM, Salmon M etal. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163: 6236-43.
15. Wright H, Alex P, Nguyen T etal. Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. Dig Dis Sci 2005; 50: 1793-803.
16. Ahlenstiel G, Woitas RP, Rockstroh J etal. CC-chemokine receptor 5 (CCR5) in hepatitis C-at the crossroads of the antiviral immune response? J Antimicrob Chemother 2004; 53: 895-8.
17. Bigger CB, Guerra B, Brasky KM etal. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004; 78: 13779-92.
18. Lichterfeld M, Leifeld L, Nischalke HD etal. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis 2002; 185: 1803-7.
19. Pham BN, Bemuau J, Durand F etal. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol 2001; 34: 537-47.
20. Tacke F, Trautwein C, Yagmur E etal. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol 2007; 22: 1256-64.
21. Vargas A, Berenguer J, Catalan P etal. Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients. J Antimicrob Chemother 2010; 65: 303-6.
22. Harvey CE, Post JJ, Palladinetti P etal. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74: 360-9.
23. Zeremski M, Petrovic LM, Chiriboga L etal. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-50.
24. Butera D, Marukian S, Iwamaye AE etal. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005; 106: 1175-82.
25. Lagging M, Romero AI, Westin J etal. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-25.
26. Romero AI, Lagging M, Westin J etal. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
27. Diago M, Castellano G, Garcia-Samaniego J etal. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55: 374-9.
28. Reiberger T, Aberle JH, Kundi M etal. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008; 13: 969-76.
29. Askarieh G, Alsio A, Pugnale P etal. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 1523-30.
30. Zeremski M, Dimova R, Brown Q etal. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009; 200: 1774-80.